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httpense.Abstract Aim of work: To study the diagnostic value of ultrasound guided biopsy in patients with
malignant pleural effusion.
Patients and methods: This study involved 40 patients with malignant pleural effusion of indeter-
minate aetiology. All patients had a contrast CT chest performed and were divided into 3 Groups
according to their radiologic appearance: GROUP 1: 10 patients having pleural effusion only.
GROUP 2: 15 patients having pleural effusion and pleural thickening. GROUP 3: 15 patients hav-
ing pleural effusion and pleural mass lesions. All 3 groups of patients underwent ultrasound exam-
ination in the Radiology department. In patients of Groups 2 and 3, ultrasound ﬂuid aspiration and
ultrasound guided core biopsy of the pleura were attempted. Patients of all 3 Groups performed
Medical thoracoscopy in the interventional pulmonology unit.
Results: InGroup 1patients,USguided biopsywas contraindicated and could not beperformeddue
to absence of pleural thickness, nodulation or masses. Thoracoscopy was performed in them all with a
sensitivity reaching 90%. In Group 2, a malignant aetiology was reached in 5/10 cases whom had ade-
quate tissue retrieval (sensitivity 50%). InGroup 3, 12/15 patients were diagnosed byUS guided biopsy
(sensitivity 80%). The mean sensitivity of US guided biopsy in both Groups was 65%. Thoracoscopy
was then performed successfully in all of patients in Groups 2 and 3 with a diagnostic sensitivity of
100% each. The mean diagnostic sensitivity of thoracoscopy for all 3 Groups was 96.7%.
Conclusion: The US guided pleural biopsy with a Tru-cut needle is simple, safe and well tolerated. It
is especially useful for patients with pleural tumour, thickened pleura, small amounts of pleural effusion
or loculated pleural effusion.
ª 2012 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
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The CXR remains the initial examination of choice in the
investigation of pleural disease and in assessing disease pro-
gress. Other radiological modalities such as ultrasound (US),
CT, magnetic resonance imaging (MRI) and positron emissionis. Production and hosting by Elsevier B.V.
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ities detected by CXR or to guide interventional procedures
[1].
Computed tomography is the best means of further assess-
ing pleural thickening seen on the CXR. Features of contrast-
enhanced CT scanning that favor malignant disease rather
than benign disease are nodular pleural thickening, mediasti-
nal pleural thickening, parietal pleural thickening greater than
1 cm, and circumferential pleural thickening [1]. Circumferen-
tial pleural thickening has been shown to be less speciﬁc for
malignancy in the presence of a pleural effusion [2].
A CT scan should be performed before drainage of the effu-
sion to dryness as pleural abnormalities surrounded by ﬂuid
will be more easily seen. CT is superior to CXR in the differ-
entiation of pleural from parenchymal disease. The detection
of pleural nodules within an effusion is indicative of malig-
nancy, whereas homogeneously echogenic effusions are most
commonly the result of a haemorrhagic effusion or an empy-
ema. CT is better than US for the evaluation of pleural thick-
ening [3].
Ultrasound is most frequently used to evaluate or guide
aspiration and drain insertion in patients with suspected pleu-
ral effusions seen on CXR. The intercostal spaces are used as
sonographic windows [4]. A small footprint probe (either
linear or phased array) allows the easiest intercostal access
and probe selection is a balance between spatial resolution
and penetration. A 7.5-MHz probe provides excellent spatial
resolution of the pleural surfaces but might not provide sufﬁ-
cient penetration in larger patients or in large effusions. A
3.5–5.0-MHz sector transducer provides a good balance and
can also be used to guide intervention [5,6].
Normal pleura are seen as an echogenic stripe comprising
both parietal and visceral pleura. During normal respiration,
there is a shimmering of inhomogeneities, described as ‘lung
sliding’, at the pleural stripe. There is also a ‘comet tail’
appearance of reverberation of the US wave distal to the
pleura. In the presence of a pneumothorax, there is loss of
the ‘lung sliding’ and ‘comet tail’ signs [7,8]. Focal pleural
masses associated with an effusion are easily seen and biopsied
under US guidance [9,10].
Thoracocentesis is diagnostic in 60% of patients with
malignant carcinomatous effusions, but in less than 30% of
patients with effusions secondary to mesothelioma [11]. If aspi-
ration cytology is negative, biopsy of associated pleural thick-
ening is required for tissue diagnosis [12]. Malignant pleural
thickening tends to predominate close to the midline and dia-
phragm, areas best avoided when performing an Abrams
biopsy. However, it is possible to take biopsy specimens safely
from these anatomical regions under radiological imaging. Im-
age-guided cutting-needle pleural biopsy has been shown to
have a higher diagnostic yield than unguided biopsies. Diag-
nostic rates of 70% have been achieved with US-guided cut-
ting-needle biopsy, and a sensitivity of 83% and a speciﬁcity
of 100% have been reported for CT-guided cutting-needle
biopsy [13].
Thoracoscopy is the investigation of choice in exudative
pleural effusions where a diagnostic pleural aspiration is incon-
clusive and malignancy is suspected [14]. Medical thoracos-
copy allows for the direct inspection of the pleura and
biopsies taken under direct vision, has a diagnostic yield supe-
rior to that of blind closed pleural biopsy and thoracocentesis.The diagnostic yield is in the order of 91–95% for malignant
disease and can be as high as 100% for pleural TB [14–17].Aim of work
To study the diagnostic value of Ultrasound guided biopsy in
patients with malignant pleural effusion.
Patients and methods
This study was conducted over a two year period from June
2010 till June 2012 in Radiology and Chest departments, Kasr
Al Aini faculty of medicine, Cairo university hospital.
The study involved 40 patients, 32 males and 8 females, suf-
fering from Malignant Pleural effusion whom underwent diag-
nostic thoracocentesis that revealed indeterminate malignant
aetiology.
All patients had a contrast CT chest performed and were di-
vided into 3 Groups according to their radiologic appearance:
Group 1: 10 patients having pleural effusion only.
Group 2: 15 patients having pleural effusion and pleural
thickening.
Group 3: 15 patients having pleural effusion and pleural
mass lesions.
All 3 Groups of patients underwent ultrasound examina-
tion in the Radiology department. Patients were placed in sit-
ting position and initial Ultrasound scanning of the pleura was
performed using 3–5 MHz curvilinear and 7–10 linear phased
array probes (Logic P 6 pro –GE health care) to assess the
amount of pleural collection, pleural thickness and any focal
thickening or frank masses.
In Group 1 patients, ultrasound guided biopsy was not
indicated due to absence of CT or ultrasound evidence of pleu-
ral involvement so only ﬁne needle aspiration (FNA) of ﬂuid
was performed using a 22 gauge spinal needle in order to re-
lieve symptoms. In patients of Groups 2 and 3, ultrasound
ﬂuid aspiration and ultrasound guided core biopsy of the
pleura were attempted. The free handed biopsy technique
was performed using 18 gauge, semi automatic Tru-cut needle
(Medikalite Tibbi Malzeme Ticareti, Turkey).
The biopsy specimens were in the form of 2–3 cylinders of
tissue 1.8 cm in length each. The amount of tissue generally
sufﬁced to provide routine hematoxylin-eosin stains on a set
of three levels, with Alcian blue/periodic acid-Schiff staining.
Spare sections for immunostaining were cut at the same time.
A panel of antibodies (cytokeratin cocktail, epithelial mem-
brane antigen [EMA], carcinoembryonic antigen, and Ber EP4,
with the additional use of cytokeratin 5/6 and thrombomodu-
lin) was applied for distinguishing metastatic carcinoma from
mesothelioma and reactive mesothelial proliferation.
All patients returned to the ward immediately after the
procedure and on a separate day, patients of all 3 Groups per-
formed Medical thoracoscopy in the interventional pulmonology
unit. Under general anaesthesia and using a single port of
entry the pleural space was entered, all amounts of pleural
ﬂuid aspirated and all surfaces of the parietal and visceral
pleura visualized. Biopsies were taken from the lesions under
direct vision and sent for histopathologic examination using
Figure 2 Ultrasound image of the pleural effusion with no
evidence of thickening or masses.
Figure 3 Thoracoscopic images of the patient showing tiny
nodules scattered along the diaphragmatic pleura (a) and parietal
pleura (b).
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guided biopsy specimens.
An intercostal chest tube was introduced into the pleural
space and patients were followed up, sometimes for several
days, until the amount of draining ﬂuid was less than 100 ml
per day before the tube was removed.
Results
40 patients were involved in this study, 22 males and 18
females. Their ages ranged between 35 and 68 years (mean
58 years) (see Figs. 1–9).
In Group 1 (10 patients) U/S biopsy was not performed,
however thoracoscopy was done for all patients showing the
following results:
In Group 2 patients (15 patients), U/S guided biopsy was
performed successfully in 10 of them with adequate tissue re-
trieval while in 5 patients there was inadequate tissue retrieval.
5 out of the 10 patients in which adequate tissue was retrieved,
showed a speciﬁc malignant aetiology (sensitivity 50%) as can
be seen in Table 2. Thoracoscopy and biopsy was then per-
formed in the 15 patients with correct diagnosis in all of them
(sensitivity 100%).
In all of patients in Group 3 (15 patients), U/S guided
biopsy was performed successfully with adequate tissue retrie-
val. A pathological diagnosis was reached in 12 patients with a
sensitivity of 80%.
Thoracoscopy was also performed in all of these patients
with a diagnosis reached in all of them (sensitivity 100%).
Table 3 shows the results of thoracoscopy compared to U/S
guided biopsy.
Discussion
Recent studies have proposed that image guidance during per-
formance of closed pleural biopsy may signiﬁcantly increase
the yield while decreasing the risk for complications when
compared to blind technique. Both transthoracic US and CT
scanning have been utilized. Modern mobile US units are
cheap and available in practically all secondary and tertiary,
as well as many primary health-care facilities, even in the
developing world [18–22].
Our study shows that in patients with Malignant pleural
effusion (MPE) and CT evidence of pleural pathology (thick-Figure 1 CT showing moderate to massive pleural effusion with
no evident pleural thickening or masses.
Figure 4 CT showing massive effusion and circumferential
pleural thickening.ening, nodules or masses), US guided closed pleural biopsy
can obtain adequate tissue for diagnosis with a mean diagnos-
tic sensitivity of 65%. The diagnostic yield is much higher in
those patients with less effusion size and larger mass lesions.
Thoracoscopy achieves higher mean diagnostic sensitivity of
96.7% in all cases of malignant pleural effusion even in Group
1 patients with no CT evidence of pleural pathology.
In our study, patients with MPE were divided into 3
Groups according to CT appearance of the pleura. Other than
Figure 5 Ultrasound image showing pleural effusion in addition
to pleural thickening with nodularity.
Figure 6 Thoracoscopic image showing diffuse parietal pleural
thickening with few pleural nodules.
Figure 7 CT showing pleural effusion + mass lesions.
Figure 8 Ultrasound images showing mass lesions affecting the
pleura in addition to minimal effusion.
Figure 9 Thoracoscopic images of the patient showing malig-
nant effusion and numerous pleural masses covering the visceral
pleura (a), parietal pleura (b) and costophrenic recess (c).
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had a smooth pleural appearance on CT whilst patients in
Groups 2 and 3 had pleural abnormalities ranging from thick-
ening to nodular or mass lesions respectively. In a recent study,
Qureshi et al. were able to identify 73% of malignant effusions
on US appearance alone.[23] They found that pleural thicken-
ing >10 mm, pleural nodularity and diaphragmatic thickening
>7 mm were highly suggestive of malignant disease.
Table 1 Results of thoracoscopic biopsies in Group 1.
Pathology No. of patients
Mesothelioma Total = 3 patients
Epithelial 2
Sarcomatous 0
Mixed (biphasic) 1
Metastatic adenocarcinoma Total = 5 patients
Lung cancer 3
Ovarian cancer 0
G IT Cancer(stomach/colon) 1
Breast cancer 1
Non hodgkin lymphoma 1 patient
Non speciﬁc inﬂammation 1 patient
Total patients 10 patients
Sensitivity 9/10 patients = 90%
CT, ultrasound and thoracoscopic ﬁndings of a patient in Group 1
(pleural effusion only).
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and could not be performed due to absence of pleural thick-
ness, nodulation or masses. Thoracoscopy was however per-
formed in them all with a sensitivity reaching 90%. 3/10 pts
had mesothelioma, 5/10 had metastatic adenocarcinoma, 1 pa-
tient had non Hodgkin lymphoma and in 1 patient the biopsy
results were non-speciﬁc (Table 1). Other studies also showed
that Thoracoscopy has a 90% to 100% sensitivity for MPE
[24,25]. In some patients, studding of pleural surfaces with
tumor can be subtle, or coexisting benign lesions could misdi-
rect biopsy sampling. For such patients, techniques that cause
metastases to ﬂuoresce can guide biopsy sampling [26,27].
In Group 2 patients with CT evidence of pleural thickening,
US guided biopsy was performed retrieving adequate tissue in
10/15 cases (66.7%) whilst in Group 3 patients with mass le-
sions of the pleura, adequate tissue was obtained in 15/15 pa-
tients (100%). Various studies have shown that adequate tissue
is obtained in 71% to 91% of closed-needle biopsy specimens
[28,29].Table 2 Results of U/S guided and thoracoscopic biopsies in Grou
Pathology No. of patients d
by thoracoscopy
Mesothelioma Total = 8 pts
Epithelial 4
Sarcomatous 2
Mixed (biphasic) 2
Metastatic adenocarcinoma Total = 7 patien
Lung cancer 3
Ovarian cancer 1
GIT cancer (stomach or colon) 1
Breast cancer 2
Non hodgkin lymphoma 0
Non speciﬁc inﬂammation 0
Total patients 15 patients
Sensitivity 15/15 patients =
CT, ultrasound and Thoracoscopic ﬁndings of a patient in Group 2 (pleIn Group 2, a malignant aetiology was reached in 5/10 cases
whom had adequate tissue retrieval (sensitivity 50%). In
Group 3, 12/15 patients were diagnosed by US guided biopsy
(sensitivity 80%). The mean sensitivity of US guided biopsy in
both Groups was 65%. Again, the malignant aetiology was
mostly Mesothelioma (Epithelial subtype more frequently in
Group 2, Sarcomatous subtype more frequently in Group 3) or
Metastatic adenocarcinoma (more frequently due to primary
lung and breast carcinoma, in both Groups) (Tables 2 and 3).
The higher diagnositic sensitivity in Group 3 agrees with var-
ious studies that showed that image-assisted biopsy is more
likely to be diagnostic in the presence of pleural thickening
>10 mm, pleural nodularity, pleural based mass lesions of
>20 cm and solid pleural tumours [23,30–32]. Thoracoscopy
was then performed successfully in all of our patients in
Groups 2 and 3 with a diagnostic sensitivity of 100%.
Chang [9] previously found the diagnostic yield of US-
guided Tru-cut pleural biopsy to be 70% for pleural neoplasia
irrespective of pleural thickening or nodularity. In a study by
Koegelenberg et al. [33] the respective yield for both US-as-
sisted Abrams or Tru-cut needle types for pleural malignancies
was comparable and relatively high being diagnostic in
approximately 83.3% of cases. Diacon et al. [30] reported an
86% sensitivity and a 100% speciﬁcity with transthoracic
ultrasonography-guided biopsy when they used a 14-gauge
cutting needle for pleura-based lesions 20 mm or greater in
diameter.
In the Helio study [34] which aimed to assess the clinical use
of ultrasonographically (US) guided core-needle biopsy, per-
formed with a one-hand automatic sampling technique, in
the diagnosis of malignant pleural mesothelioma (MPM), a
sensitivity of 77%, speciﬁcity of 88%, accuracy of 80%, posi-
tive predictive value of 100%, and negative predictive value of
57% were found. This differed from the results regarding diag-
nosis of mesothelioma in Group 2 patients of our study (with
CT evidence of pleural thickening only) where US guided
biopsy had a sensitivity of 3/8 (37.5%) (Table 2). In Group 3
patients, however, results regarding diagnosis of mesothelioma
were similar, with US guided biopsy sensitivity increasing to
7/10 patients (70%) (Table 3) due to the presence of evident
nodules and mass lesions on CT examination making thep 2.
iagnosed No. of patients diagnosed by U/S
guided biopsy
Total = 3 pts
1
2
0
ts Total = 2 patients
1
0
1
0
0
0
5 patients
100% 5/10 patients = 50%
ural effusion ± pleural thickening).
Table 3 Results of U/S guided and thoracoscopic biopsies in Group 3.
Pathology No. of patients diagnosed
by thoracoscopy
No. of patients diagnosed
by U/S guided biopsy
Mesothelioma Total = 10 pts Total = 7 pts
Epithelial 3 3
Sarcomatous 4 4
Mixed (biphasic) 3 0
Metastatic adenocarcinoma Total = 4 patients Total = 4 patients
Lung cancer 2 2
Ovarian cancer 0 0
GIT cancer (stomach or colon) 0 0
Breast cancer 2 2
Non hodgkin lymphoma 1 patient 1 patient
Non speciﬁc inﬂammation 0 0
Total patients 15 patients 12 patients
Sensitivity 15/15 patients = 100% 12/15 patients = 80%
CT, ultrasound and Thoracoscopic ﬁndings of a patient in Group 3 (pleural effusion ± mass lesions).
Mean sensitivity of medical thoracoscopy for Groups 1–3 = 96.7%.
Mean sensitivity of U/S guided biopsy for Groups 2 and 3 = 65%.
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that for malignant mesothelioma extending at least 20 mm in
any accessible dimension on US, the diagnostic yield of US
guided Tru-cut biopsy may be as high as 100%.
Throughout our study, medical thoracoscopy was per-
formed in all 3 Groups of patients with a mean diagnostic sen-
sitivity of 96.7%. It was the only means of diagnosis
(sensitivity 90%) in Group 1 patients whom had indeterminate
malignant pleural effusion with no CT evidence of pleural
thickening or masses thus preventing the use of US guided
biopsy. In the other Groups (2 and 3), the diagnostic sensitivity
of thoracoscopy reached 100%, thus ensuring exact aetiology
determination in all of the cases of malignant effusion.
Another point worth mentioning is that for diagnosis of
mesothelioma and classiﬁcation of its subtype, a large pleural
biopsy specimen is often necessary which can usually be ob-
tained thoracoscopically. Immunohistochemical staining pro-
vides essential information in the diagnostic evaluation.
Some specimens could require electron microscopy to differen-
tiate mesotheliomas from adenocarcinomas or ﬁbrous pleuri-
tis. Mesothelioma subtype classiﬁcation becomes important
in centers that recommend aggressive trimodality therapy with
extrapleural pneumonectomy for the epithelial but not the
mixed or sarcomatoid subtypes [35].
Canto et al. [36] considered thoracoscopy to be an invasive
study, not suitable for dense adhesions in the pleural space and
usually calls for general anaesthesia. They found that with the
use of US guidance, pleural biopsy with Tru-cut needle was
done precisely and safely even in the presence of only small
amount of loculated pleural effusion.
In conclusion, thoracoscopy has a superior diagnostic yield
for pleural malignancy and is therefore considered by many to
be the investigation of choice in exudative pleural effusions
where a thoracocentesis was nondiagnostic and particularly
when malignancy is suspected. Furthermore, it allows for the
direct inspection of the pleura. Access to thoracoscopy is, how-
ever, limited in many parts of the world, as signiﬁcant re-
sources and expertise are required. Blind closed pleuralbiopsy has a modest yield. Recent studies suggest that image
guidance improves the yield, particularly for malignancy. An
US-guided second thoracocentesis combined with an US-
guided pleural biopsy with a Tru-cut needle may therefore be
an acceptable alternative to thoracoscopy. Cases that remain
undiagnosed warrant thoracoscopy.
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